

# Benoit Busser

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6905189/publications.pdf>

Version: 2024-02-01

44  
papers

1,548  
citations

304368

22  
h-index

315357

38  
g-index

61  
all docs

61  
docs citations

61  
times ranked

2530  
citing authors

#	ARTICLE	IF	CITATIONS
1	Visualizing the cerebral distribution of chemical elements: A challenge met with LIBS elemental imaging. <i>Journal of Neuroscience Methods</i> , 2022, 379, 109676.	1.3	5
2	Near-infrared emitting fluorescent homobimetallic gold(I) complexes displaying promising in vitro and in vivo therapeutic properties. <i>European Journal of Medicinal Chemistry</i> , 2021, 220, 113483.	2.6	11
3	Iron Dysregulation in Human Cancer: Altered Metabolism, Biomarkers for Diagnosis, Prognosis, Monitoring and Rationale for Therapy. <i>Cancers</i> , 2020, 12, 3524.	1.7	24
4	The Multifaceted Roles of Copper in Cancer: A Trace Metal Element with Dysregulated Metabolism, but Also a Target or a Bullet for Therapy. <i>Cancers</i> , 2020, 12, 3594.	1.7	126
5	Aza-BODIPY: A New Vector for Enhanced Theranostic Boron Neutron Capture Therapy Applications. <i>Cells</i> , 2020, 9, 1953.	1.8	27
6	Radiation Dose Enhancement Is a Potent Radiotherapeutic Effect of Rare Earth Composite Nanoscintillators in Preclinical Models of Glioblastoma. <i>Advanced Science</i> , 2020, 7, 2001675.	5.6	36
7	Water-Soluble Aza-BODIPYs: Biocompatible Organic Dyes for High Contrast <i>In Vivo</i> NIR-II Imaging. <i>Bioconjugate Chemistry</i> , 2020, 31, 1088-1092.	1.8	60
8	LIBS imaging applications. , 2020, , 329-346.		7
9	Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth. <i>Theranostics</i> , 2020, 10, 2008-2028.	4.6	15
10	Gold nanoclusters as a contrast agent for image-guided surgery of head and neck tumors. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 20, 102011.	1.7	29
11	Laser-induced breakdown spectroscopy for human and animal health: A review. <i>Spectrochimica Acta, Part B: Atomic Spectroscopy</i> , 2019, 152, 123-148.	1.5	104
12	The pyrrolopyrimidine colchicine-binding site agent PP-13 reduces the metastatic dissemination of invasive cancer cells in vitro and in vivo. <i>Biochemical Pharmacology</i> , 2019, 160, 1-13.	2.0	17
13	Nuclear translocation of IGF1R by intracellular amphiregulin contributes to the resistance of lung tumour cells to EGFR-TKI. <i>Cancer Letters</i> , 2018, 420, 146-155.	3.2	20
14	Elemental imaging using laser-induced breakdown spectroscopy: A new and promising approach for biological and medical applications. <i>Coordination Chemistry Reviews</i> , 2018, 358, 70-79.	9.5	108
15	Characterization of foreign materials in paraffin-embedded pathological specimens using in situ multi-elemental imaging with laser spectroscopy. <i>Modern Pathology</i> , 2018, 31, 378-384.	2.9	23
16	1555...Tracking aetiology and exposure for idiopathic lung diseases: recent advances from in situ multi-elemental imaging with laser spectrometry. , 2018, , .		0
17	Anticancer properties of lipid and poly( $\epsilon$ -caprolactone) nanocapsules loaded with ferrocenyl-tamoxifen derivatives. <i>Journal of Pharmacy and Pharmacology</i> , 2018, 70, 1474-1484.	1.2	8
18	Multi-elemental imaging of paraffin-embedded human samples by laser-induced breakdown spectroscopy. <i>Spectrochimica Acta, Part B: Atomic Spectroscopy</i> , 2017, 133, 40-44.	1.5	49

#	ARTICLE	IF	CITATIONS
19	Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2157-2165.	1.9	22
20	Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications. <i>BioMed Research International</i> , 2017, 2017, 1-8.	0.9	39
21	Identification of pyrrolopyrimidine derivative PP-13 as a novel microtubule-destabilizing agent with promising anticancer properties. <i>Scientific Reports</i> , 2017, 7, 10209.	1.6	16
22	Laser spectroscopy for in situ elemental imaging of lung tissue: a promising technology. , 2017, , .		0
23	Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6843-6855.	1.0	30
24	Lower risk of cutaneous squamous cell carcinomas induced by vemurafenib in non melanoma patients. <i>Annals of Oncology</i> , 2016, 27, vi391.	0.6	0
25	Identification of a pyrrolo-pyrimidin derivative to overcome the resistance to apoptosis in non-small cell lung cancer cells. <i>European Journal of Cancer</i> , 2016, 61, S140.	1.3	0
26	3D Imaging of Nanoparticle Distribution in Biological Tissue by Laser-Induced Breakdown Spectroscopy. <i>Scientific Reports</i> , 2016, 6, 29936.	1.6	89
27	Access to molecular guided therapy for Langerhans cell histiocytosis patients. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, e31.	0.6	4
28	High throughput screening to identify new compounds with proapoptotic activity in resistant lung cancer cells. <i>Revue Des Maladies Respiratoires</i> , 2015, 32, 324.	1.7	0
29	A Recombinant Fungal Lectin for Labeling Truncated Glycans on Human Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0128190.	1.1	25
30	Laser spectrometry for multi-elemental imaging of biological tissues. <i>Scientific Reports</i> , 2014, 4, 6065.	1.6	117
31	The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism. <i>International Journal of Cancer</i> , 2014, 134, 2560-2571.	2.3	50
32	495: AKT and gefitinib resistance in mutant KRAS non-small cell lung cancers through mechanisms dependent of acetylation. <i>European Journal of Cancer</i> , 2014, 50, S119.	1.3	0
33	Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, e97-e99.	0.6	37
34	Adequacy of CT-guided biopsies with histomolecular subtyping of pulmonary adenocarcinomas: Influence of ATS/ERS/IASLC guidelines. <i>Lung Cancer</i> , 2013, 82, 69-75.	0.9	44
35	Comparison of COBAS 4800 KRAS, TaqMan PCR and High Resolution Melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 329-335.	1.4	32
36	Identification of a Novel Complex BRAF Mutation Associated With Major Clinical Response to Vemurafenib in a Patient With Metastatic Melanoma. <i>JAMA Dermatology</i> , 2013, 149, 1403.	2.0	20

#	ARTICLE	IF	CITATIONS
37	The multiple roles of amphiregulin in human cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2011, 1816, 119-131.	3.3	148
38	Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. <i>Journal of Pathology</i> , 2011, 225, 83-95.	2.1	43
39	Unusual Increased $\hat{I}^2$ -Globulins in an Elderly Patient. <i>Clinical Chemistry</i> , 2011, 57, 948-951.	1.5	2
40	101: Identification of differential pathways in mucinous and non-mucinous subtypes of lung adenocarcinoma suggested new therapeutic strategies. <i>Bulletin Du Cancer</i> , 2010, 97, S81-S82.	0.6	2
41	Amphiregulin Promotes BAX Inhibition and Resistance to Gefitinib in Non-small-cell Lung Cancers. <i>Molecular Therapy</i> , 2010, 18, 528-535.	3.7	49
42	Amphiregulin Promotes Resistance to Gefitinib in NonSmall Cell Lung Cancer Cells by Regulating Ku70 Acetylation. <i>Molecular Therapy</i> , 2010, 18, 536-543.	3.7	38
43	210 Identification and characterization of amphiregulin as a new biomarker of resistance to gefitinib in non-small cell lung cancers. <i>European Journal of Cancer, Supplement</i> , 2010, 8, 55.	2.2	0
44	The increasing role of amphiregulin in non-small cell lung cancer. <i>Pathologie Et Biologie</i> , 2009, 57, 511-512.	2.2	14